Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib 400mg vs 600mg in Newly Diagnosed CML-CP
NCT05353205Phase 4Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Flumatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Early Molecular Response Rate at 3 months. Started Nov 2021; status: recruiting.
02
Drugs
Flumatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05353205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353205.